

Immune complexes in sera and synovial fluids of patients with rheumatoid arthritis. Radioimmunoassay with monoclonal rheumatoid factor.

H S Luthra, ... , G G Hunder, E A Samayoa

J Clin Invest. 1975;**56**(2):458-466. <https://doi.org/10.1172/JCI108112>.

Research Article

Evidence for the presence of immune complexes in blood, synovial fluid, and tissues of patients with rheumatoid arthritis (RA) includes low complement levels in blood and effusions, deposition of immunoreactants in tissues and vessel walls, precipitate formation after addition of monoclonal rheumatoid factor (mRF) to serum or synovial fluid. To quantitate immune complex-like material in RA patients, we developed a radioimmunoassay based on inhibition by test samples of the interaction of (125I)aggregated IgG (agg IgG) and mRF coupled to cellulose. This method could measure immune complexes of human antibody with hemocyanine prepared in vitro. The assay was not influenced by presence of polyclonal RF in test samples, nor by freezing and thawing. Normal levels of immune complex-like material in serum were less than 25 mug agg IgG EQ/ML. 12 of 51 RA sera examined (26%) contained more than 25 mug/ml. The presence of this material in RA sera was found to correlate with severity of disease, as measured by anatomical stage and functional class. There was an inverse correlation of the material with serum C4 level. Rheumatoid synovial fluids generally contained higher levels than serum, and five of 23 contained very much higher levels. The frequency of elevated levels of immune complex-like material in sera of patients with systemic lupus erythematosus (2 of 29) and with miscellaneous vasculitides (2 of [...])

Find the latest version:

<https://jci.me/108112/pdf>



Immune Complexes in Sera and Synovial Fluids of Patients with Rheumatoid Arthritis

RADIOIMMUNOASSAY WITH MONOCLONAL RHEUMATOID FACTOR

HARVINDER S. LUTHRA, FREDERIC C. McDUFFIE, GENE G. HUNDER, and
EDUARDO A. SAMAYOA

*From the Departments of Medicine, Immunology, and Microbiology, Mayo
Foundation, Rochester, Minnesota 55901*

ABSTRACT Evidence for the presence of immune complexes in blood, synovial fluid, and tissues of patients with rheumatoid arthritis (RA) includes low complement levels in blood and effusions, deposition of immunoreactants in tissues and vessel walls, and precipitate formation after addition of monoclonal rheumatoid factor (mRF) to serum or synovial fluid. To quantitate immune complex-like material in RA patients, we developed a radioimmunoassay based on inhibition by test samples of the interaction of [125 I]aggregated IgG (agg IgG) and mRF coupled to cellulose. This method could measure immune complexes of human antibody with hemocyanin prepared in vitro. The assay was not influenced by presence of polyclonal RF in test samples, nor by freezing and thawing. Normal levels of immune complex-like material in serum were less than 25 μ g agg IgG eq/ml. 12 of 51 RA sera examined (26%) contained more than 25 μ g/ml. The presence of this material in RA sera was found to correlate with severity of disease, as measured by anatomical stage and functional class. There was an inverse correlation of the material with serum C4 level. Rheumatoid synovial fluids generally contained higher levels than serum, and five of 23 contained very much higher levels. The frequency of elevated levels of immune complex-like material in sera of patients with systemic lupus erythematosus (2 of 29) and with miscellaneous vasculitides (2 of 21) was much lower than in RA, suggesting that mRF ex-

hibits a specificity for only certain kinds of immune complexes. The reason for this apparent specificity may explain such distinctive features of RA as the high frequency of polyclonal RF, the lack of immune complex nephritis, and the generally normal levels of serum complement.

INTRODUCTION

Sera and synovial fluids from patients with rheumatoid arthritis (RA)¹ have been shown to possess high molecular weight material that contains immunoglobulins and may represent immune complexes (1-7). Winchester, Agnello, and Kunkel have shown a close correlation between the presence of this material in synovial fluid and low levels of complement (4). These high molecular weight complexes may well play a significant role in the chronic inflammatory process that characterizes this disease. However, the precise role of these presumed complexes in RA is still not known. One significant limitation to learning more about the nature of this material and its relationship to the clinical features of RA has been the lack of a sensitive, easily performed, and reproducible quantitative method for measuring it. Winchester et al. (4) measured the amount of material in synovial fluid precipitable with monoclonal rheumatoid factor (mRF) by the quantitative precipitin test but this method is cumbersome and requires relatively large amounts of the reagent, mRF.

Results of this work were presented in part at the 6th Pan-American Congress on Rheumatic Diseases, Toronto, Ontario, 18 June 1974.

Received for publication 31 December 1974 and in revised form 10 April 1975.

¹ Abbreviations used in this paper: agg IgG, heat-aggregated IgG; m, monoclonal; RA, rheumatoid arthritis; RBAF, rheumatoid biologically active factor; RF, rheumatoid factor; SLE, systemic lupus erythematosus.

These same authors (5) have also reported the use of monoclonal rheumatoid factors in double immunodiffusion for demonstrating these immune complexes in rheumatoid sera and synovial fluids. Although useful in detecting this material, the technique is not quantitative, and weak precipitin reactions are hard to read with confidence. As a result, we have developed a solid-phase radioimmunoassay (8), in which an mRF conjugated to microcrystalline cellulose and heat-aggregated IgG (agg IgG) served as reagent. With this technique, we were able to demonstrate the presence of immune complex-like material in the sera of about one-fourth of patients with RA and to show that its presence is related to indices of disease severity.

METHODS

mRF: isolation and conjugation to microcrystalline cellulose. Monoclonal IgM, kappa, rheumatoid factor (mRF) was separated from 5 ml of serum of a patient with severe cutaneous vasculitis and an uncharacterized lymphoproliferative disorder. It was dialyzed against 0.1 M glycine HCl, pH 3.0, buffer for 12 h at 4°C and then applied to a Sephadex G-200 column in the same buffer. The exclusion volume protein peak was conjugated to Avicel microcrystalline cellulose (Brinkmann Instruments, Inc., Westbury, N. Y.) by a method based on that of Axen, Porath, and Ernback (9). We used mRF, microcrystalline cellulose, and cyanogen bromide in a ratio of 1:10:80. After 48 h, the conjugate was washed and the amount of bound protein calculated by subtraction of recovered unbound protein. About 70% of the added protein was usually bound to cellulose.

Preparation of [¹²⁵I]aggregated IgG. Aggregated IgG was prepared by heating human Cohn fraction II (Miles Laboratories, Inc., Elkhart, Ind.) at 63°C (temperature inside tube) for 10 min and subsequently precipitating at 0.62 M sodium sulfate at 25°C (10). The aggregates were dissolved in neutral buffer, applied to a 5–40% sucrose density gradient, and centrifuged at 283,000 *g* (bottom of the tubes) for 6 h in an International B-60 ultracentrifuge in a SW 283 rotor (40,000 rpm) (Damon/IEC, Needham Heights, Mass.). Tubes containing aggregates of approximately 25S were pooled and used in subsequent studies. Aggregated IgG was radiolabeled with ¹²⁵I by the method of Hunter and Greenwood (11). We mixed 2.0 mg of agg IgG in 5.0 ml of 0.1 M Tris, 0.2 M NaCl, pH 8.0, buffer with 0.56 mCi of carrier-free ¹²⁵I with constant stirring. Then 0.5 mg of chloramine-T in 0.1 ml of pH 7.0 phosphate-buffered saline was added, and exactly 1 min later 0.25 mg of sodium metabisulphite in 0.1 ml of phosphate-buffered saline. The mixture was passed through a 1 × 25-cm Sephadex G-25 column, and the tubes containing the first radioactive peak were pooled. The specific activity of most preparations was about 0.2 mCi/mg.

Solid phase radioimmunoassay. Optimal amounts of conjugated mRF and agg IgG were determined by preliminary trials. Reagents were dissolved or suspended in 0.075 M phosphate, 0.075 M NaCl, pH 7.5, buffer containing 1% bovine serum albumin. Capped polystyrene tubes, 11 × 63 mm (Luckman Limited, Burgess Hill, Sussex, England) were used, as they gave the least nonspecific binding of several batches of tubes tested. Into each tube were added in order 0.5 ml of test solution, 0.5 ml of [¹²⁵I]agg IgG containing 0.27 μg of protein, and 0.5 ml of conjugated mRF

containing 2.0 μg of protein bound to 27 μg of cellulose. The tubes were incubated with continuous rotation for 1 h at 37°C and 12 h at 4°C. After centrifugation and washing three times with 1.0-ml portions of buffer, the conjugate was resuspended and the radioactivity counted in a Nuclear-Chicago automatic scintillation counter (Nuclear-Chicago Corp., Des Plaines, Ill.). Before assay, human sera and effusions were analyzed for 7S IgG content by the radial immunodiffusion technique (12) and were diluted to a final 7S IgG concentration of 60 μg/ml. Portions of 0.5 ml of this solution were used for assay. This latter procedure was carried out to compensate for any interference by 7S IgG in the sample with the assay (see Results).

A standard curve was prepared for each assay by adding different amounts of agg IgG (1–150 μg) to a normal human serum of known 7S IgG content and then diluting these samples for assay. The amount of reacting material in test sera and fluids was calculated by reference to the plot of counts per minute vs. agg IgG content. Results were expressed as micrograms of agg IgG equivalent per milliliter in the original specimen. These standard curves were submitted to regression analysis, and if the coefficient of correlation was less than 0.98, the results of the assay were discarded.

Density gradient ultracentrifugation. Density gradient ultracentrifugation was carried out on a 5–30% sucrose density gradient in 0.1 M Tris, 0.2 M NaCl, pH 8.0, buffer, on which we layered 0.5 ml of sample, before centrifugation at 283,000 *g* (at the bottom of the tube) for 12 h at 4°C in an International B-60 ultracentrifuge in a SW 283 rotor. The positions of IgG and IgM in normal human serum were determined by radial immunodiffusion and used as 7S and 19S markers.

Collection of samples. All sera were allowed to clot at room temperature and were stored at 4°C after addition of 1% sodium azide as preservative. All synovial fluids were treated with hyaluronidase, 0.2 μg/ml of fluid, and stored at 4°C after addition of 1% azide. 102 normal human sera were collected from healthy adults donating blood to the blood bank. Plasma was collected from hospitalized patients undergoing diagnostic tests. Specimens of rheumatic disease patients were identified by review of clinical records. Sera and synovial fluids were also obtained from patients with RA, systemic lupus erythematosus (SLE), and miscellaneous vasculitides whose sera and synovial fluids had been obtained previously for various tests and had been stored at –70°C.

Analysis of clinical data. Clinical data were abstracted from each patient's record. The anatomical stage of disease of patients with RA was estimated by reviewing the available X-rays of involved joints (13). The modified 1958 criteria of Ropes, Bennett, Cobb, Jacox, and Jessar (14) were used to classify these patients as having probable, definite, or classical RA.

C4 determination. C4 levels were determined by radial immunodiffusion in plates containing agar mixed with monospecific antiserum to C4 made by us.

RESULTS

Isolation of mRF and conjugation. The results of chromatography of the serum containing mRF on Sephadex G-200 are shown in Fig. 1. The mRF eluted in the first peak. It contained a small amount of bound IgG, which, however, did not interfere with the subsequent assay.




FIGURE 1 Chromatography of serum containing mRF on Sephadex G-200 at pH 3.0. Symbols at top indicate results of testing effluent fractions against appropriate antisera or against agg IgG in double immunodiffusion.

Effect of 7S IgG on the assay for immune complexes. Fig. 2 shows the results obtained in an experiment in which samples of agg IgG of known concentration in buffer were tested in the assay. A characteristic inhibition curve was obtained, maximum sensitivity being obtained in the range of 2-7 μ g/ml. Because of known reactivity of RF with 7S IgG (15, 16) and the presence of large amounts of 7S IgG in serum, it was essential to examine the effect of 7S IgG on the immunoassay for aggregates. Thus the assay was simultaneously carried out on a sample of 7S IgG cleared of any contaminating aggregates by ultracentrifugation at 40,000 rpm for 3 h. This 7S IgG did produce some inhibition of binding of [125 I]agg IgG to mRF; but as shown in Fig. 2, 50 μ g of 7S IgG was required to produce the same inhibition of binding as less than 1 μ g of agg IgG. As a result, however, of this demonstrated binding of 7S IgG to the conjugated mRF, a correction for this effect on assays of biological materials was built into the assay by




FIGURE 2 Inhibition of binding of [125 I]agg IgG by solid phase mRF in the presence of 7S IgG (---) or aggregated IgG (—).




FIGURE 3 Hemocyanin-human antihemocyanin precipitin curve. To 1.0-ml samples of human antihemocyanin, portions of Limulus polyphemus hemocyanin (LPH) were added. The washed immune precipitates were analyzed for protein by spectrophotometry at 277 nm, and the supernates assayed for aggregated IgG equivalent by solid phase radioimmunoassay. —X— OD_{277nm} of immune precipitate. Bars represents amount of aggregated IgG equivalent measured in each supernate by radioimmunoassay.

diluting all samples to a constant 7S IgG content of 60 μ g/ml and introducing this same amount of 7S IgG into all aggregate samples used in preparation of each standard curve.

Hemocyanin-antihemocyanin complexes. Though the results in Fig. 2 demonstrated that artificially aggregated IgG could be measured in this assay, it was necessary to show that the method could actually quantitate antigen-antibody complexes. Thus supernates from a Limulus polyphemus hemocyanin (LPH)-human antihemocyanin precipitin curve were examined for immune complexes (Fig. 3). At the equivalence point, 0.125 mg/ml of hemocyanin, as determined by examining the supernates in double immunodiffusion (17), no reactivity with mRF was detected by radioimmunoassay. However, immune complexes were measurable in the supernates both in region of antibody excess (tubes containing less than 0.125 mg LPH) and in region of antigen excess (tubes containing more than 0.125 mg LPH).

Effect of polyclonal RF on the immunoassay. Since rheumatoid sera and fluids generally contain large amounts of polyclonal RF, we examined the effect of polyclonal RF on the assay. Such RF might bind to the [125 I]agg IgG in the tubes and inhibit binding to the mRF conjugate. Polyclonal RF was isolated from the serum of a patient with RA by the same technique used for mRF described above. Different amounts of this RF were added to normal human serum to yield final RF titers of 1:250-1:64,000. As shown in Fig. 4, there was no effect on binding of [125 I]agg IgG to conjugated mRF up to a titer of 1:16,000. Even in serum with an

RF titer of 1:64,000, there was only a 25% reduction in binding. We also examined the effect of polyclonal RF on the determination of complexes in a serum known to contain such material. The data in Table I demonstrate the negligible effect of polyclonal RF on the results obtained with a serum containing hemocyanin-antihemocyanin complexes.

Reproducibility of immunoassay and effects of heating and freezing sera. 14 sera containing 1 to more than 150 μg agg IgG eq/ml were assayed several times. Of these, two were assayed seven times each and the variation in the results was less than 5%. 10 sera were assayed twice with less than 5% difference between the individual samples in each pair. Two additional sera gave results which varied significantly. One, assayed twice, showed results of 1 and 25 $\mu\text{g}/\text{ml}$ of agg IgG equivalent and the other yielded results of 50, 68, and 11 μg of agg IgG eq/ml on different occasions.

Heating sera at 56°C for 60 min to inactivate complement resulted in the appearance of inhibitory activity, probably resulting from the formation of aggregates. Therefore, all sera and fluids were used without heating.

Freezing at -20°C and thawing sera seven times did not result in any change in the amount of reacting material, as compared with that of samples stored at 4°C. Thus use of sera and synovial fluids stored at -70°C and thawed two to three times did not affect the results.

Density gradient ultracentrifugation. In order to estimate the size of reacting material, rheumatoid sera found to contain material reacting in the assay were applied to 5-30% sucrose density gradients and the fractions assayed by immunoassay. Fig. 5a and b dem-




FIGURE 4 Effect of adding isolated polyclonal RF on the inhibition of binding of [^{125}I]agg IgG to conjugated mRF. Thick vertical bars represent amount of binding of [^{125}I]agg IgG in presence of normal serum to which polyclonal RF has been added to produce the final RF titers shown by the thin horizontal bars in the upper part of the figure. NHS, normal human serum.

TABLE I
Effect of Addition of Polyclonal RF on Measurement of Hemocyanin-Antihemocyanin Immune Complexes


Rheumatoid factor	Agg IgG eq.	
	No hemocyanin added	Hemocyanin (0.25 mg/ml)
final titer ⁻¹	$\mu\text{g}/\text{ml}$	
None	11	83
320	14	76
640	16	83
1,280	12	92

Purified polyclonal IgM RF was added to human anti-hemocyanin to produce RF titers shown above. 0.25 mg hemocyanin was added to produce moderate antigen excess as determined from quantitative precipitin curve (see Fig. 3).


onstrate that immune complex-like material of both intermediate (approximately 11S) and heavy size (19S and larger) was measured by the assay in rheumatoid sera.

Assay of human sera. The results of assay of several groups of human sera are shown in Fig. 6. Of 102 normal human sera only 2 (2%) contained more than 25 μg agg IgG eq/ml. Thus we chose 25 μg of agg IgG eq/ml as the upper limit of normal. Among the hospitalized nonrheumatic disease patients, sera of 6 of 67 (9%) contained more than 25 μg agg IgG eq/ml. These six patients had the following diseases; two, subacute bacterial endocarditis with glomerulonephritis; one, recurrent pulmonary emboli with an unclassified myeloproliferative disorder; one, regional enteritis with Pseudomonas pneumonia; one, inactive rheumatic heart disease; and one, clinically normal. This last patient had an RF titer 1:20,480, negative lupus-erythematosus cell test, and no antinuclear antibody.

Among the sera from patients with rheumatoid arthritis, 12 of 46 (26%) contained more than 25 μg agg IgG eq/ml, 11 of these patients was seropositive, and all twelve had definite or classical RA. For statistical analyses, the rheumatoid patients were divided into two groups: one, patients whose sera contained 25 μg agg IgG eq/ml or less, and two, patients whose sera contained more than 25 μg agg IgG eq/ml. The duration of disease for the two groups was found to be longer in the patients with immune complexes at $P=0.05$ level, by a two-sided rank sum test. An association between severity of disease as measured by functional class (Fig. 7) and anatomical stage (Fig. 8) on the one hand and presence of immune complexes on the other was demonstrable by the χ^2 test ($P=0.025$ and 0.05, respectively). No correlation was found with the erythrocyte sedimentation rate or RF titer (IgG or IgM). However, comparison of the C4 levels between



a



b

FIGURE 5a and b Radioimmunoassay results of sucrose density gradient fractions on two sera from patients with rheumatoid arthritis. Tube 1 represents bottom tube. ↑↑ indicate position of 19S IgM and 7S IgG.

the two groups revealed a significant difference ($P = 0.001$ by a two-sided rank sum test). Using Spearman's rank correlation coefficient, we found agg IgG and C4 to be negatively correlated ($r_s = -0.449$, $P = 0.003$). Clinical data of the 12 rheumatoid patients with elevated levels of agg IgG are shown in Table II.

Only 2 of 29 (7%) SLE sera and 2 of 21 (10%) miscellaneous vasculitides sera showed significant reactivity with mRF conjugate (Fig. 6). One positive patient with SLE had minimal focal membranous changes on renal biopsy and a low serum complement level, while the other had clinically inactive disease with normal total hemolytic complement and no renal involvement. Of 24 SLE patients with less than 25 µg agg IgG eq/ml on whom serum complement was determined, 7 had low levels. Of the patients in the miscellaneous vasculitides




FIGURE 6 Solid phase radioimmunoassay results of sera from normal individuals and patients with several diseases.

group who had elevated levels of agg IgG, one had a systemic arteritis and the other Löfller's syndrome with pulmonary vasculitis.

Synovial fluids. On assay of 40 synovial fluids, we found that 5 of 23 (22%) from patients with RA, none




FIGURE 7 Correlation between the amount of aggregated IgG equivalent in sera of patients having RA and the functional class of their disease. For χ^2 square test, classes III and IV were combined. The analysis showed an association between functional class and aggregated IgG equivalent level ($P = 0.025$).

TABLE II
Clinical Features of Rheumatoid Patients with High Levels of Immune Complex-Like Material in Serum

Patient	Sex	Age	Duration of RA	ARA class and stage	RF titer*	LE cell	ANA titer†	Agg IgG	Extra-articular manifestations
<i>no</i>		<i>yr</i>	<i>yr</i>					<i>μg eq/ml</i>	
L168	F	57	12	III; II	1:128,000	Hem. bodies	1:256	>150	Sjögren's syndrome and leg ulcers
L169	F	68	17	II; III	1:128,000	Neg.	ND	>150	None
L189	F	78	37	III; III	1:256,000	ND	1:128 mixed	>150	Sjögren's syndrome
L174	M	64	20	II; III	1:64	Neg.	ND	120	Sjögren's syndrome
L171	F	42	12	II; III	1:4,000	Pos.	1:256 mixed	93	Felty's syndrome and basilar lung fibrosis
L173	F	58	11	II; II	1:4,000	Pos.	ND	50	Sjögren's syndrome
L172	F	54	30	III	1:4,000	ND	1:32 mixed	48	Leg ulcers and neuropathy
L311	M	50	2	II; II	1:8,000	ND	ND	43	None
L167	M	59	13	III; III	1:400	Neg.	Neg.	35	Basilar lung fibrosis
L82	F	71	10	II; II	Neg.	Rosettes	Neg.	33	Leg ulcers
L262	F	45	20	II; III	1:512	Neg.	ND	27	Felty's syndrome
L339	M	30	1½	II; III	1:8,000	Rosettes	1:32 mixed	26	None

* Rheumatoid factor by sensitized human cell test (Ripley).

† Antinuclear antibody by immunofluorescent test.

ND, Not done.

of 6 patients with SLE, and none of 11 synovial fluids from patients with miscellaneous diseases showed more than 25 μg agg IgG eq/ml. The miscellaneous group consisted of five degenerative joint diseases, two effu-

sions of undetermined etiology, and one each of pseudogout, psoriasis, ankylosing spondylitis, and intermittent hydroarthrosis (Fig. 9).

We were not able to establish a statistically significant relationship between C4 and agg IgG in rheumatoid




FIGURE 8 Correlation between the amount of aggregated IgG equivalent in sera of patients having RA and the anatomical stage of their disease. For χ square test stages 0 and I and stages III and IV were combined. The χ square test indicated an association between the anatomical stage and the level of aggregated IgG equivalent ($P = 0.05$).




FIGURE 9 Amount of aggregated IgG equivalent in paired sera and synovial fluids from patients with RA and from patients with other diseases.

synovial fluids by Spearman's rank correlation coefficient, as had been possible for serum. A two-sided rank sum test did reveal that mean complement levels were significantly lower in fluids containing immune complexes ($P = 0.05$).

Fig. 9 shows results of comparing paired sera and synovial fluids in rheumatoid and miscellaneous disease patients. Four rheumatoid synovial fluids contained significant amounts of agg IgG activity and each contained more than was present in the corresponding serum. Thus it appears unlikely that the synovial fluid material represented only transport of immune complex material from the serum.

DISCUSSION

In the last few years both direct and indirect evidence has accumulated for the presence of immune complexes in patients with RA. Fish, Michael, Gewurz, and Good (18) and Rodman, Williams, Bilka, and Müller-Eberhard (19) used the immunofluorescent technique to demonstrate the presence of immunoglobulins (IgG and IgM) and complement in the synovial membrane of patients with RA and suggested that the presence of these immunoreactants represented deposits of immune complexes of unknown origin. Conn, McDuffie, and Dyck (20) found similar deposits in the walls of nutrient vessels of sural nerves of patients with rheumatoid neuropathy. Previously Pekin and Zvaifler (21, 22) and Hedberg (23) had reported disproportionately low levels of hemolytic complement in the synovial fluids as compared to the sera in patients with RA. Subsequently, Franco and Schur (24) and Hunder and McDuffie (2) reported low serum levels of complement in certain rheumatoid patients: observations consistent with complement consumption by immune aggregates.

Direct evidence of the presence of immune complex-like material in RA had been provided as early as 1957 by Franklin, Holman, Müller-Eberhard, and Kunkel (1), who demonstrated by analytical ultracentrifugation the presence of a high molecular weight material (22S) in the serum of RA patients, a material which could be reversibly dissociated into 7S and 19S components by exposure to pH 3.0 or to 4–6 M urea. Chodirker and Tomasi in 1963 (25) identified in certain rheumatoid sera an intermediate-size complex (11S), which dissociated into a 7S component at an acid pH.

That immune complexes possessing biological activity might be present in RA has been shown by Bauman and Broder (7), who isolated high molecular weight material by G-200 Sephadex chromatography from rheumatoid sera that was capable of initiating a complement-dependent reaction resulting in release of histamine from guinea pig lung. This material, rheumatoid biologically active factor (RBAF), was found in both sera

and synovial fluids. Subsequently, the presence of RBAF was found to correlate with disease activity (26) and to disappear as a result of successful treatment (27, 28).

A simpler technique for demonstration of immune complexes was introduced in 1967 by Hannestad (3). He found that certain high-titer RFs, capable of precipitating agg IgG, produced precipitin reactions with certain rheumatoid synovial fluids. Winchester, Kunkel, and Agnello (5) reported that mRFs were superior reagents for demonstrating such material. These workers isolated the reactive material and showed that it contained IgG, some of which represented IgG RF.

All of these techniques have certain drawbacks that limit their usefulness in studying the relationship of immune complex-like material to disease. Analytical ultracentrifugation is relatively insensitive and too cumbersome for analysis of large numbers of samples. The bioassay technique of Bauman and Broder is very complex and undoubtedly will prove difficult to standardize. Immunodiffusion is nonquantitative and in our experience weak bands are difficult to interpret with confidence.

The solid phase radioimmunoassay developed by us has numerous advantages over other techniques, in that it is quantitative, easily performed, sensitive, reproducible, and readily usable for analysis of many samples. The advantage of the radioimmunoassay over the quantitative precipitin test (4) lies in the small amounts of test sample and of mRF needed for each test and the ease and rapidity of the method, which does not require setting up the numerous points required for complete precipitin curves. The disadvantages are that it is necessary to perform a preliminary analysis on each sample for 7S IgG by radial immunodiffusion and that the assay requires a particular mRF. Such reagents are not readily available. Furthermore, future experience may show some differences in the specificity of these RFs for IgG complexes. In preliminary experiments we have not found our RF to be specific for any IgG subclass. The [125 I]agg IgG used in the assay contains material of a range of sizes (approximately 20–30S) chosen to approximate that of most of the material found in the sera tested (see Fig. 5a). We have not investigated the effect the use of such a standard might have on the quantitative aspects of measurement of immune complexes of larger or smaller size. Larger complexes may be overestimated and smaller complexes underestimated in the assay as performed. Cowdery, Treadwell, and Fritz (29) have recently described a radioimmunoassay for immune complexes in which rheumatoid serum containing polyclonal RF is used as the primary reagent, and the RF-immune complex aggregate is precipitated by rabbit anti-human IgM. Probably because of the low affinity of the polyclonal RF used, these authors could

not employ it to detect immune complexes in sera containing RF.

The most important question raised by the present work is whether the material we have measured is truly an immune complex, and if so, what is the antigen. At present we cannot answer either of these questions with confidence. The experiments with the hemocyanin-anti-hemocyanin system demonstrated that the technique is capable of quantitating immune complexes in human serum. The density gradient ultracentrifugation studies showed that the material being measured is considerably heavier than 7S IgG. Furthermore, in one rheumatoid serum known to contain 22S and 11S complexes, the assay detected reactive material in both regions (Fig. 5a). The nature of the antigen present in immune complexes in RA sera remains a crucial question, of course. The work of Winchester et al. (5) supports the belief that a complex composed of IgG and IgG and IgM RF certainly represents some of the reactive material. Whether we are also detecting additional antigen-antibody systems that may be relevant to the pathogenesis of RA is still unknown. The lack of close correlation between RF titer and the amount of immune complex-like material present in rheumatoid sera favors the presence of such other systems, as do other observations in our laboratory showing a lack of relationship between RF content and complement-fixing activity of rheumatoid sera (30).

The frequency of positive reactions in the sera of our rheumatoid patients (26%) was somewhat less than in the group of patients reported by Winchester et al. (50%) (5). Without more data on the populations of patients studied, our lower percentage of abnormal results cannot be explained. The correlation between the presence of immune complex-like material in sera and indices of disease severity as well as low serum complement suggests that it may be related in some way to the disease process. It does not appear to be identical with the RBAF described by Bauman and Broder (7). Measurements performed on 20 sera and 20 synovial fluids, on which assays for RBAF had been performed in their laboratory, did not show a close relationship between the presence of RBAF and agg IgG equivalent.

The low levels of immune complex-like material in the sera of patients with SLE, only 2 of 29 (7%), were at first somewhat surprising, in view of the evidence that SLE is an immune complex disease. However, Winchester et al. (5) found that only 8% of sera from patients with hypocomplementemic SLE showed such precipitin reactions. Clq, which detects complexes in SLE sera but not in RA sera (31), and RFs appear to measure different types of immune complexes. Size of the complexes present may be an important determinant in reactivity with these two reagents. Winchester et al.

(5) have suggested that mRF is able to precipitate with somewhat smaller complexes than Clq. However, certain SLE sera contain 7S material capable of precipitating with Clq (31).

Recently two other methods of measuring immune complexes have been described. Nydegger, Lambert, Gerber, and Miescher (32) have developed a radioimmunoassay for immune complexes in which [¹²⁵I]Clq is used as reagent. These workers were able to detect reacting material in sera from two-thirds of the rheumatoid patients tested (33). Theofilopoulos, Wilson, Bokisch, and Dixon (34) described the use of complement receptors on B lymphocytes for the assay of immune complexes in sera of both rabbits with experimental serum sickness and humans with glomerulonephritis. It will undoubtedly be necessary to utilize several methods of detecting such polydisperse material as immune complexes before it can be determined what each one is capable of measuring.

ACKNOWLEDGMENTS

We thank Hilton W. Brumfield for able technical assistance and Dr. I. Broder for performing analyses for RBAF on sera and synovial fluids. Dr. Peter O'Brien provided help with the statistical analysis.

Extramural financial support was provided by the National Institute of Arthritis and Metabolic and Digestive Diseases (AM17174) and the Minnesota Chapter of the Arthritis Foundation.

REFERENCES

1. Franklin, E. C., H. R. Holman, H. J. Müller-Eberhard, and H. G. Kunkel. 1957. An unusual protein component of high molecular weight in the serum of certain patients with rheumatoid arthritis. *J. Exp. Med.* 105: 425-438.
2. Hunder, G. G., and F. C. McDuffie. 1973. Hypocomplementemia in rheumatoid arthritis. *Am. J. Med.* 54: 461-472.
3. Hannestad, K. 1967. Presence of aggregated γ G-globulin in certain rheumatoid synovial effusions. *Clin. Exp. Immunol.* 2: 511-529.
4. Winchester, R. J., V. Agnello, and H. G. Kunkel. 1970. Gamma globulin complexes in synovial fluids of patients with rheumatoid arthritis: partial characterization and relationship to lowered complement levels. *Clin. Exp. Immunol.* 6: 689-706.
5. Winchester, R. J., H. G. Kunkel, and V. Agnello. 1971. Occurrence of γ -globulin complexes in serum and joint fluid of rheumatoid arthritis patients: use of monoclonal rheumatoid factors as reagents for their demonstration. *J. Exp. Med.* 134: 286s-295s.
6. Kunkel, H. G., H. J. Müller-Eberhard, H. H. Fudenberg, and T. B. Tomasi. 1961. Gammaglobulin complexes in rheumatoid arthritis and certain other conditions. *J. Clin. Invest.* 40: 117-129.
7. Bauman, R., and I. Broder. 1968. Studies into the occurrence of soluble antigen-antibody complexes in disease. III. Rheumatoid arthritis and other diseases. *Clin. Exp. Immunol.* 3: 555-569.
8. Wide, L., and J. Porath. 1966. Radioimmunoassay of proteins with the use of Sephadex-coupled antibodies. *Biochim. Biophys. Acta.* 130: 257-259.

9. Axen, R., J. Porath, and S. Ernback. 1967. Chemical coupling of peptides and proteins to polysaccharides by means of cyanogen halides. *Nature (Lond.)*. 214: 1302-1304.
10. Christian, C. L. 1958. Characterization of the "reactant" (gammaglobulin factor) in the F II precipitin reaction and the F II tanned sheep cell agglutination test. *J. Exp. Med.* 108: 139-157.
11. Hunter, W. M., and F. C. Greenwood. 1962. Preparation of I^{125} labelled human growth hormone of high specific activity. *Nature (Lond.)*. 194: 495-496.
12. Mancini, G., A. O. Carbonara, and J. F. Heremans. 1965. Immunochemical quantitation of antigens by single radial immunodiffusion. *Immunochemistry*. 2: 235-254.
13. Steinbrocker, O., C. H. Traeger, and R. C. Batterman. 1949. Therapeutic criteria in rheumatoid arthritis. *J. Am. Med. Assoc.* 140: 659-662.
14. Ropes, M. W., G. A. Bennett, S. Cobb, R. Jacox, and R. A. Jassar. 1958. Revision of diagnostic criteria for rheumatoid arthritis. *Bull. Rheum. Dis.* 9: 175-176.
15. Hannestad, K. 1968. Rheumatoid factors reacting with autologous native γ G-globulin and joint fluid γ G aggregates. *Clin. Exp. Immunol.* 3: 671-690.
16. Normansell, D. E., and D. R. Stanworth. 1966. Ultracentrifugal studies of the reactions of rheumatoid factor with native human γ G-globulin. *Immunology*. 10: 527-533.
17. Auernheimer, A. H., and F. O. Atchley. 1962. Modifications of micro agar precipitin test. *Am. J. Clin. Pathol.* 38: 548-553.
18. Fish, A. J., A. F. Michael, H. Gewurz, and R. A. Good. 1966. Immunopathologic changes in rheumatoid arthritis synovium. *Arthritis Rheum.* 9: 267-280.
19. Rodman, W. S., R. C. Williams, Jr., P. J. Bilka, and H. J. Müller-Eberhard. 1967. Immunofluorescent localization of the third and fourth component of complement in synovial tissue from patients with rheumatoid arthritis. *J. Lab. Clin. Med.* 69:141-150.
20. Conn, D. L., F. C. McDuffie, and P. J. Dyck. 1972. Immunopathologic study of sural nerves in rheumatoid arthritis. *Arthritis Rheum.* 15: 135-143.
21. Pekin, T. J., Jr., and N. J. Zvaifler. 1962. Measurement of hemolytic complement in synovial fluids. *Arthritis Rheum.* 5: 314. (Abstr.)
22. Pekin, T. J., Jr., and N. J. Zvaifler. 1964. Hemolytic complement in synovial fluid. *J. Clin. Invest.* 43: 1372-1382.
23. Hedberg, H. 1963. Studies on the depressed hemolytic complement activity of synovial fluid in adult rheumatoid arthritis. *Acta Rheumatol. Scand.* 9: 165-193.
24. Franco, A. E., and P. H. Schur. 1971. Hypocomplementemia in rheumatoid arthritis. *Arthritis Rheum.* 14: 231-238.
25. Chodirker, W. B., and T. B. Tomasi, Jr. 1963. Low-molecular-weight rheumatoid factor. *J. Clin. Invest.* 42: 876-884.
26. Gordon, D. A., D. A. Bell, R. Baumal, and I. Broder. 1969. Studies into the occurrence of soluble antigen-antibody complexes in disease. IV. Correlation between the rheumatoid biologically active factor and clinical features of rheumatoid arthritis. *Clin. Exp. Immunol.* 5: 57-66.
27. Urowitz, M. B., D. A. Gordon, and I. Broder. 1973. Studies into the occurrence of soluble antigen-antibody complexes in disease. V. Second assessment of correlation between the rheumatoid biologically active factor (RBAF) and the clinical features of rheumatoid arthritis. *Arthritis Rheum.* 16: 225-230.
28. Russell, M. Lynn, D. A. Gordon, and I. Broder. 1974. Studies into the occurrence of soluble antigen-antibody complexes in disease. VII. Clinical laboratory correlations of immunoglobulin complexes in rheumatoid synovial fluid. *J. Rheum.* 1: 153-158.
29. Cowdery, J. S., Jr., P. E. Treadwell, and R. B. Fritz. 1975. A radioimmunoassay for human antigen-antibody complexes in clinical material. *J. Immunol.* 114: 5-9.
30. McDuffie, F. C., G. G. Hunder, and R. J. Clark. 1974. Complement fixing material in sera of patients with rheumatoid arthritis, non-identity with rheumatoid factors. *Clin. Res.* 22: 643a. (Abstr.)
31. Agnello, V., D. Koffler, J. W. Eisenberg, R. J. Winchester, and H. G. Kunkel. 1971. C1q precipitin in the sera of patients with systemic lupus erythematosus and other hypocomplementemic states; characterization of high and low molecular weight types. *J. Exp. Med.* 134: 228s-241s.
32. Nydegger, U. E., P. H. Lambert, H. Gerber, and P. A. Miescher. 1974. Circulating immune complexes in the serum in systemic lupus erythematosus and in carriers of hepatitis B antigens. Quantitation by binding to radio-labeled C1q. *J. Clin. Invest.* 54: 297-309.
33. Lambert, P. H., U. E. Nydegger, L. H. Perrin, J. McCormick, K. Fehr, and P. A. Miescher. 1975. Complement activation in seropositive and seronegative rheumatoid arthritis. 125 I-C1q binding capacity and complement breakdown-products in serum and synovial fluid. *Rheumatology*. In press.
34. Theofilopoulos, A. N., C. B. Wilson, V. A. Bokisch, and F. J. Dixon. 1974. Binding of soluble immune complexes to human lymphoblastoid cells. II. Use of Raji cells to detect circulating immune complexes in animal and human sera. *J. Exp. Med.* 140: 1230-1244.